MA46245A - Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron) - Google Patents
Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron)Info
- Publication number
- MA46245A MA46245A MA046245A MA46245A MA46245A MA 46245 A MA46245 A MA 46245A MA 046245 A MA046245 A MA 046245A MA 46245 A MA46245 A MA 46245A MA 46245 A MA46245 A MA 46245A
- Authority
- MA
- Morocco
- Prior art keywords
- agonists
- interferon gene
- cyclic dinucleotides
- gene stimulator
- stimulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016234553 | 2016-12-01 | ||
| JP2017107216A JP2018090562A (ja) | 2016-12-01 | 2017-05-30 | 環状ジヌクレオチド |
| US201762589300P | 2017-11-21 | 2017-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46245A true MA46245A (fr) | 2019-07-24 |
Family
ID=66179467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046245A MA46245A (fr) | 2016-12-01 | 2017-12-01 | Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron) |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10980825B2 (fr) |
| EP (2) | EP3868384A1 (fr) |
| JP (2) | JP6633255B1 (fr) |
| KR (1) | KR102640802B1 (fr) |
| CN (1) | CN110325543B (fr) |
| AU (1) | AU2017370004B2 (fr) |
| BR (1) | BR112019011120A2 (fr) |
| CA (1) | CA3045762A1 (fr) |
| CL (1) | CL2019001485A1 (fr) |
| CO (1) | CO2019007032A2 (fr) |
| CY (1) | CY1124196T1 (fr) |
| DK (1) | DK3512861T3 (fr) |
| EC (1) | ECSP19046507A (fr) |
| ES (1) | ES2866948T3 (fr) |
| HR (1) | HRP20210726T1 (fr) |
| HU (1) | HUE054450T2 (fr) |
| IL (1) | IL267020B (fr) |
| JO (1) | JOP20170192A1 (fr) |
| LT (1) | LT3512861T (fr) |
| MA (1) | MA46245A (fr) |
| MX (1) | MX2019006397A (fr) |
| MY (1) | MY190460A (fr) |
| PE (1) | PE20210255A1 (fr) |
| PH (1) | PH12019501222A1 (fr) |
| PL (1) | PL3512861T3 (fr) |
| PT (1) | PT3512861T (fr) |
| RS (1) | RS61818B1 (fr) |
| SI (1) | SI3512861T1 (fr) |
| UA (1) | UA126390C2 (fr) |
| WO (1) | WO2018100558A2 (fr) |
| ZA (1) | ZA201904311B (fr) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| EP3481402A4 (fr) | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| US20200113924A1 (en) * | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| WO2018138685A2 (fr) * | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Dinucléotides cycliques utilisés en tant qu'agonistes de sting |
| CA3053568A1 (fr) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Dinucleotides cycliques utilises en tant qu'agonistes du stimulateur de la signalisation dependante du gene de l'interferon |
| WO2019043634A2 (fr) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Di-nucléotides cycliques en tant que stimulateurs de modulateurs de gènes d'interféron |
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019084060A1 (fr) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugués et leurs procédés d'utilisation pour l'administration sélective d'agents immunomodulateurs |
| US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| EP3727401A4 (fr) * | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques utilisés comme agonistes sting |
| WO2019123340A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
| CA3084582A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucleotides 2'3' cycliques ayant une liaison phosphonate activant la proteine adaptatrice de sting |
| EP3505188A1 (fr) | 2017-12-29 | 2019-07-03 | Invivogen | Conjugués de dinucléotide pro-cycliques pour l'induction de la cytokine |
| EP3759109B1 (fr) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Composés de pyrrolizine substitués en tant qu'inhibiteurs de réplication du virus de l'hépatite b |
| MX2020009796A (es) | 2018-03-23 | 2021-01-15 | Codiak Biosciences Inc | Vesiculas extracelulares que comprenden agonista de estimulador de genes de interferon (sting). |
| WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチド |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| AU2019337051B2 (en) | 2018-09-06 | 2023-11-23 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
| EP3849615A1 (fr) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions pour le traitement d'une maladie avec des conjugués immunostimulants |
| CA3113425A1 (fr) | 2018-09-21 | 2020-03-26 | Shanghai De Novo Pharmatech Co., Ltd. | Analogue dinucleotidique cyclique, composition pharmaceutique associee et utilisation |
| CN113453724A (zh) | 2018-09-27 | 2021-09-28 | 皮埃尔法布雷医药公司 | 基于磺酰基马来酰亚胺的连接子和相应的偶联物 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| EP3934757B1 (fr) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
| CN113747925A (zh) | 2019-03-21 | 2021-12-03 | 科迪亚克生物科学公司 | 胞外囊泡缀合物及其用途 |
| US20220168415A1 (en) | 2019-03-21 | 2022-06-02 | Codiak Biosciences, Inc. | Extracellular vesicles for vaccine delivery |
| WO2020191369A1 (fr) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3962493A2 (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Métodes de modulation de l'activité immunitaire |
| US11787833B2 (en) | 2019-05-09 | 2023-10-17 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| JP2022532192A (ja) | 2019-05-10 | 2022-07-13 | 武田薬品工業株式会社 | 抗体薬物複合体 |
| EP3972695A1 (fr) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
| CA3142513A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Proteines de fusion flt3l-fc et procedes d'utilisation |
| US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| WO2021003445A1 (fr) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Vésicules extracellulaires ciblant des lymphocytes t et leurs utilisations |
| JP2022538690A (ja) | 2019-07-05 | 2022-09-05 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| CA3146490A1 (fr) | 2019-07-09 | 2021-01-14 | Takeda Pharmaceutical Company Limited | Administration d'un agoniste de sting et d'inhibiteurs de points de controle |
| EP3999118A1 (fr) * | 2019-07-19 | 2022-05-25 | Immunesensor Therapeutics, Inc. | Conjugués anticorps-agonistes de sting et leur utilisation en immunothérapie |
| WO2021034804A1 (fr) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
| WO2021046426A1 (fr) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Agonistes de sting dinucléotidiques cycliques attachés à un pd-1 ou à des anticorps ctla-4 |
| EP4034276A1 (fr) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Procédés de production de vésicules extracellulaires |
| KR20220094221A (ko) | 2019-09-25 | 2022-07-05 | 코디악 바이오사이언시즈, 인크. | 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀 |
| AU2020355240A1 (en) | 2019-09-25 | 2022-04-21 | Lonza Sales Ag | Extracellular vesicle compositions |
| WO2021062058A1 (fr) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Agoniste de sting comprenant des exosomes pour le traitement de troubles neuro-immunologiques |
| CR20220129A (es) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
| WO2021067644A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polythérapie comprenant des conjugués immunostimulants |
| US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021168274A1 (fr) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
| IL296124A (en) * | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a drug including a novel cyclic dinucleotide derivative |
| WO2021184017A1 (fr) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Vésicules extracellulaires pour le traitement de troubles neurologiques |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| CA3169348A1 (fr) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Promedicaments de nucleosides de 4'-c-substitue-2-halo-2'-desoxyadenosine et leurs procedes de fabrication et d'utilisation |
| EP4134098A4 (fr) | 2020-04-10 | 2024-05-15 | Ono Pharmaceutical Co | Méthode de cancérothérapie |
| WO2021216572A1 (fr) | 2020-04-20 | 2021-10-28 | Massachusetts Institute Of Technology | Compositions lipidiques pour l'administration de composés agonistes de sting et leurs utilisations |
| WO2021237100A1 (fr) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Procédés d'administration ciblée de vésicules extracellulaires dans le poumon |
| WO2021261996A2 (fr) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Conjugués de saponine à base de nhs |
| KR20230043113A (ko) * | 2020-06-24 | 2023-03-30 | 사프렘 테크놀로지스 비.브이. | 의약용 사포닌 유도체 |
| AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
| US20220119426A1 (en) | 2020-08-07 | 2022-04-21 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| EP4295917A3 (fr) | 2020-08-07 | 2024-02-28 | Tambo, Inc. | Agents bioorthogonaux de trans-cyclooctène et leurs utilisations dans le traitement du cancer et l'immunothérapie |
| JPWO2022050300A1 (fr) | 2020-09-02 | 2022-03-10 | ||
| IL301190A (en) * | 2020-09-08 | 2023-05-01 | Univ Texas | Multi-purpose vehicles for sting activation and their uses |
| WO2022066883A1 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations |
| WO2022066928A2 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
| US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
| WO2022066934A2 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
| KR102558127B1 (ko) * | 2020-10-23 | 2023-07-24 | 아주대학교산학협력단 | 아릴피페라진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
| MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
| AU2021383424A1 (en) | 2020-11-18 | 2023-06-08 | Takeda Pharmaceutical Company Limited | Administration of sting agonist, checkpoint inhibitors, and radiation |
| TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3220923A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
| EP4137499A1 (fr) | 2021-08-17 | 2023-02-22 | Ustav organicke chemie a biochemie AV CR, v.v.i. | 7-déazaadénine 7-substitués contenant 2,3 dinucléotides cycliques |
| WO2023056468A1 (fr) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Vésicule extracellulaire comprenant un agoniste de sting marqué au cholestérol |
| WO2024020164A2 (fr) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Agonistes du récepteur des glucocorticoïdes et leurs conjugués |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL90359A0 (en) | 1988-05-26 | 1989-12-15 | University Patents Inc | Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and their production |
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| WO2004006955A1 (fr) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Anticorps super humanises |
| EP1620544B1 (fr) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | Agents modifies d'arni |
| WO2005005450A1 (fr) | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | Procede de synthese d'un bisdinucleoside cyclique |
| EP1651242A2 (fr) | 2003-07-28 | 2006-05-03 | David K. R. Karaolis | Procede permettant d'attenuer la virulence d'agents pathogenes microbiens et d'inhiber la formation d'un biofilm microbien |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| EP1768998A2 (fr) | 2004-04-27 | 2007-04-04 | Alnylam Pharmaceuticals Inc. | Oligonucleotides mono-brin et double brin a fraction 2-arylpropyle |
| US20090012038A1 (en) | 2004-10-18 | 2009-01-08 | Spormann Alfred M | Methods for microbial biofilm destruction and interference with microbial cellular physiology |
| EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
| US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| US8034921B2 (en) | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
| WO2009133560A1 (fr) | 2008-04-29 | 2009-11-05 | Smart Assays | Dérivés de bis-(nucléotide monophosphate) cycliques non hydrolysables et perméables et leurs utilisations |
| US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
| KR101834890B1 (ko) * | 2009-10-23 | 2018-04-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항ｇｃｃ 항체 분자와 관련 조성물 및 방법 |
| US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
| KR20220045091A (ko) | 2011-11-18 | 2022-04-12 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴（ＴＴＲ） 관련 질병을 치료하기 위한 ＲＮＡｉ 제제, 조성 및 그의 사용방법 |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| WO2013185052A1 (fr) | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compositions et procédés pour immunothérapie anticancéreuse |
| US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
| WO2014093936A1 (fr) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation |
| CA2895175C (fr) | 2012-12-19 | 2021-06-01 | Board Of Regents, The University Of Texas System | Ciblage pharmaceutique d'une voie de signalisation de dinucleotide cyclique chez un mammifere |
| JP6153116B2 (ja) | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| BR112015027327B1 (pt) * | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | Composto, modulador de cgas, composição farmacêutica compreendendo o referido composto ou modulador |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
| JP6400082B2 (ja) * | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| US9549944B2 (en) * | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| WO2015017652A1 (fr) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Cristaux sting et modulateurs associés |
| US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| WO2015074145A1 (fr) | 2013-11-22 | 2015-05-28 | Brock University | Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral |
| JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド |
| EP3233882B1 (fr) * | 2014-12-16 | 2019-10-30 | Kayla Therapeutics | Dinucléotides cycliques fluorés pour l'induction de la cytokine |
| EP3233191A1 (fr) | 2014-12-16 | 2017-10-25 | Invivogen | Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer |
| SG11201704287TA (en) * | 2014-12-22 | 2017-07-28 | Basf Se | Use of a chemical mechanical polishing (cmp) composition for polishing of cobalt and / or cobalt alloy comprising substrates |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR20170129802A (ko) | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법 |
| FR3037784B1 (fr) * | 2015-06-29 | 2017-12-15 | Gexfix Sa | Dispositif de fixation externe dynamique d'osteosynthese |
| WO2017011444A1 (fr) | 2015-07-13 | 2017-01-19 | The Wistar Institute Of Anatomy And Biology | Méthodes et compositions pour le traitement de cancers des lymphocytes b |
| WO2017011622A1 (fr) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Composés et compositions qui induisent rig-i et d'autres récepteurs de reconnaissance de motifs |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| US20170146519A1 (en) | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
| MA52157A (fr) * | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
| CA3007311A1 (fr) | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation |
| WO2017106740A1 (fr) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Procédés servant à identifier des inhibiteurs de la production d'interféron dépendant du stimulateur du gène d'interféron |
| CN109451740B (zh) | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
| WO2017123657A1 (fr) | 2016-01-11 | 2017-07-20 | Gary Glick | Dinucléotides cycliques pour traiter des affections associées à l'activité sting comme le cancer |
| IL280430B2 (en) * | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| WO2017165506A1 (fr) | 2016-03-23 | 2017-09-28 | Academia Sinica | Nanoparticules polymères à enveloppe mince et leurs utilisations |
| CR20200045A (es) | 2016-04-07 | 2020-03-11 | Glaxosmithkline Ip Dev Ltd | AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472) |
| EP3440072B1 (fr) | 2016-04-07 | 2020-01-29 | GlaxoSmithKline Intellectual Property Development Ltd | Amides hétérocycliques utiles en tant que modulateurs de protéine |
| WO2017186711A1 (fr) | 2016-04-25 | 2017-11-02 | Invivogen | Nouveaux complexes de composés immunostimulateurs, et leurs utilisations |
| EP3452492A1 (fr) | 2016-05-05 | 2019-03-13 | Novartis AG | Dérivés d'amatoxine et leurs conjugués à utiliser en tant qu'inhibiteurs de l'arn polymérase |
| WO2018009466A1 (fr) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
| WO2018009652A1 (fr) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| EP3481402A4 (fr) | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| WO2018013887A1 (fr) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
| CR20190071A (es) | 2016-07-15 | 2019-10-29 | Sperovie Biosciences Inc | Compuestos, composiciones y métodos para el tratamiento de enfermedades |
| WO2018045204A1 (fr) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Analogues de dinucléotides cycliques pour traiter des états associés à l'activité de la piqûre (stimulateur des gènes de l'interféron) |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| RS62410B1 (sr) | 2016-10-04 | 2021-10-29 | Merck Sharp & Dohme | Benzo[b]tiofenska jedinjenja kao agonisti sting |
| US11001605B2 (en) | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
| JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
| US20200113924A1 (en) | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| AU2017378782A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| WO2018119117A1 (fr) | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Procédés de production de dinucléotides cycliques |
| WO2018140831A2 (fr) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Conjugués ciblant les tumeurs et leurs méthodes d'utilisation |
| JP7213188B2 (ja) | 2017-01-27 | 2023-01-26 | ヤンセン バイオテツク，インコーポレーテツド | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
| WO2018138685A2 (fr) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Dinucléotides cycliques utilisés en tant qu'agonistes de sting |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| CA3053568A1 (fr) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Dinucleotides cycliques utilises en tant qu'agonistes du stimulateur de la signalisation dependante du gene de l'interferon |
| CN106667914B (zh) | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
| JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| WO2018198084A1 (fr) | 2017-04-27 | 2018-11-01 | Lupin Limited | Composés di-nucléotidiques cycliques avec des nucléobases tricycliques |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| WO2019043634A2 (fr) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Di-nucléotides cycliques en tant que stimulateurs de modulateurs de gènes d'interféron |
| US10953032B2 (en) | 2017-08-31 | 2021-03-23 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019046496A1 (fr) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | Dinucléotides cycliques utilisés en tant qu'agents anticancéreux |
| CN111212839A (zh) | 2017-09-15 | 2020-05-29 | 艾杜罗生物科技公司 | 吡唑并嘧啶酮化合物及其用途 |
| MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
-
2016
- 2016-12-01 JO JOP/2017/0192A patent/JOP20170192A1/ar unknown
-
2017
- 2017-12-01 EP EP21157239.1A patent/EP3868384A1/fr active Pending
- 2017-12-01 KR KR1020197019077A patent/KR102640802B1/ko active IP Right Grant
- 2017-12-01 SI SI201730756T patent/SI3512861T1/sl unknown
- 2017-12-01 LT LTEP17817176.5T patent/LT3512861T/lt unknown
- 2017-12-01 MX MX2019006397A patent/MX2019006397A/es unknown
- 2017-12-01 EP EP17817176.5A patent/EP3512861B1/fr active Active
- 2017-12-01 JP JP2019527462A patent/JP6633255B1/ja active Active
- 2017-12-01 MA MA046245A patent/MA46245A/fr unknown
- 2017-12-01 RS RS20210562A patent/RS61818B1/sr unknown
- 2017-12-01 ES ES17817176T patent/ES2866948T3/es active Active
- 2017-12-01 HU HUE17817176A patent/HUE054450T2/hu unknown
- 2017-12-01 PE PE2019001164A patent/PE20210255A1/es unknown
- 2017-12-01 MY MYPI2019003124A patent/MY190460A/en unknown
- 2017-12-01 CN CN201780074714.9A patent/CN110325543B/zh active Active
- 2017-12-01 PT PT178171765T patent/PT3512861T/pt unknown
- 2017-12-01 DK DK17817176.5T patent/DK3512861T3/da active
- 2017-12-01 UA UAA201907162A patent/UA126390C2/uk unknown
- 2017-12-01 PL PL17817176T patent/PL3512861T3/pl unknown
- 2017-12-01 CA CA3045762A patent/CA3045762A1/fr active Pending
- 2017-12-01 BR BR112019011120A patent/BR112019011120A2/pt unknown
- 2017-12-01 AU AU2017370004A patent/AU2017370004B2/en active Active
- 2017-12-01 WO PCT/IB2017/057588 patent/WO2018100558A2/fr active Application Filing
-
2018
- 2018-11-09 US US16/185,258 patent/US10980825B2/en active Active
-
2019
- 2019-05-30 IL IL267020A patent/IL267020B/en unknown
- 2019-05-31 PH PH12019501222A patent/PH12019501222A1/en unknown
- 2019-05-31 CL CL2019001485A patent/CL2019001485A1/es unknown
- 2019-06-28 EC ECSENADI201946507A patent/ECSP19046507A/es unknown
- 2019-06-28 ZA ZA2019/04311A patent/ZA201904311B/en unknown
- 2019-06-28 CO CONC2019/0007032A patent/CO2019007032A2/es unknown
- 2019-12-11 JP JP2019223919A patent/JP7229907B2/ja active Active
-
2020
- 2020-10-07 US US17/065,242 patent/US11666594B2/en active Active
-
2021
- 2021-05-06 CY CY20211100384T patent/CY1124196T1/el unknown
- 2021-05-10 HR HRP20210726TT patent/HRP20210726T1/hr unknown
-
2023
- 2023-05-01 US US18/310,467 patent/US20240066047A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46245A (fr) | Dinucléotides cycliques comme agonistes (stimulateur des gènes de l'interféron) | |
| EP3585379A4 (fr) | Dinucléotides cycliques utilisés en tant qu'agonistes du stimulateur de la signalisation dépendante du gène de l'interféron | |
| IL272850A (en) | Artificial nucleic acid molecules | |
| HK1253065A1 (zh) | 靶向蛋白質的化合物、其組合物、方法和用途 | |
| MA52157A (fr) | Dinucléotides cycliques de purine utilisés comme modulateurs de sting | |
| MA42608A (fr) | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) | |
| MY192848A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| BR112017016638A2 (pt) | anticorpos direcionados contra o gene de ativação de linfócitos 3 (lag-3) | |
| PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| WO2015143046A3 (fr) | Procédés et compositions pour la régulation sélective de l'expression de protéine à doigt à zinc | |
| WO2015112896A3 (fr) | Méthodes et compositions pour des séquences guidant le ciblage de cas9 | |
| MX2017016811A (es) | Metodos para mejorar el rendimiento del animal. | |
| EP3464313A4 (fr) | Nucléotides modifiés 5 '-cyclo-phosphonate | |
| MA42597A (fr) | 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA45656A (fr) | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 | |
| EA201790847A1 (ru) | Композиции и способы лечения с применением пролекарств тизоксанида, его аналога или соли | |
| IL277921A (en) | RNA new small operators | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| IL280105A (en) | Cyclic dinucleotides as STING agonists | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| PH12016501326A1 (en) | (s)-3'-methyl-abscisic acid and esters thereof | |
| PH12016502592A1 (en) | 3'-substituted-abscisic acid derivatives | |
| MX2019006783A (es) | Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirim idin-2-ona. | |
| GB201715609D0 (en) | Postie's friend |